New Studies Demonstrate 75% Myopia Management Efficacy with Chinese Children after 12 Months and No Evidence of Rebound Effect in North American Children for SightGlass Vision DOT™ Lenses
Company Presents Latest Data at the ARVO 2025 Annual Meeting
DALLAS, May 1, 2025—A new clinical study from SightGlass Vision demonstrates that its Diffusion Optics Technology™ (DOT 0.2) spectacle lenses are highly effective for myopia management, achieving 75% efficacy in Chinese children after 12 months, and a separate study demonstrates no evidence of rebound (i.e., myopia progression did not accelerate after ceasing wear) in North American children. This unique optical intervention uses thousands of light-scattering elements to reduce contrast signaling on the retina—an evidence-backed mechanism of action to slow myopia progression in children. Both studies are being presented at the ARVO 2025 Annual Meeting, one of the most prestigious forums for the ophthalmology, optometry, and ocular science communities.
“Eye care professionals in a growing number of markets trust DOT™ lenses, and this latest data further builds the well-established science behind our technology. Clinical investigators have seen an extremely positive response to our approach among Chinese children—a remarkable 75% reduction in myopia progression after 1-year of wear. Additionally, researchers observed treatment benefit was retained after North American children stopped DOT™ lens wear. This is a durable, evidence-based myopia management intervention that can improve children’s lives worldwide,” said Andrew Sedgwick, chief executive officer of SightGlass Vision.
Building on its four-year North American CYPRESS study, SightGlass Vision initiated the CATHAY trial to examine DOT™ lens efficacy in China. Titled “Control of Myopia Using Contrast Modulation Spectacle Lenses in a Chinese Population: 12-Month Results” (Laughton D, et al.), the study evaluated 186 myopic children, aged 6 to 13 at initiation, across five hospitals in China. The results showed a significant slowing of myopia progression when using DOT™ lenses compared to single vision spectacle lenses. Specifically, there was a 75% reduction in cycloplegic spherical equivalent refraction (cSER), with a decrease of −0.48D (p<0.0001), and a 74% reduction in axial length (AL), with a decrease of 0.26 mm (p<0.0001). These preliminary findings from the CATHAY study, which is expected to continue for 24 months, support the outcomes from the first year of the CYPRESS study.
Seeking to address one of the more common clinical questions as the myopia management category matures, SightGlass Vision also evaluated if any significant rebound effect occurred following treatment with DOT™ lenses. “Myopia Progression One-Year After Cessation of Contrast Modulation Spectacle Lenses” (Hill J, et al) followed a subset of children who participated in the CYPRESS multicenter trial for an additional 12 months. The control continued to wear single-vision spectacle lenses while the DOT™ group was crossed over to the same. After one year of discontinued DOT™ spectacle lens wear, cSER and AL progression among this test group reverted to age-normative rates observed in the control, indicating no statistically or clinically significant rebound effect. This offers an important reassurance to clinicians and parents when making myopia management decisions.
In addition, the company continues to invest in foundational research related to myopia management. This includes new work on short-term subfoveal choroidal thickness (SFCT) variation, which may act as an early biomarker for successfully controlling eye growth and myopia progression. “Subfoveal Choroidal Thickening After Short-Term Wear of Contrast and Defocus-Modulating Myopia Control Spectacle Lenses” (Desiato A, et al) evaluated 31 children who wore DOT™ and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for 12 hours per day. Both groups exhibited a significant increase in SFCT after one week compared to single vision lens use, suggesting that contrast and defocus modulation of the retinal image may help slow myopia progression.
“Week after week, we are seeing mounting enthusiasm for DOT™ spectacle lenses from eye care professionals. These relevant and rigorous scientific outcomes, combined with their own experiences, helps them more quickly adopt and confidently recommend the technology,” said Sedgwick.
Taking place in Salt Lake City, Utah, from May 4-8, ARVO 2025 is expected to draw thousands of researchers, clinicians, educators, and students in ophthalmology, vision science, and optometry from around the globe.
SightGlass Vision’s patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, Israel, and Canada, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica. For more information, visit SightGlassVision.com.
About SightGlass Vision
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.
SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for SightGlass Vision
+1-585-545-1815 or mike@mcdougallpr.com